RenovoRx, Inc.(RNXT)

Biotechnology · Mountain View, CA

$1.39-0.08 (-5.44%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:48:02.146Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:48:02.146Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 62,623,253
Total debt · period ending 2026-06-30: 259,000
Cash · period ending 2026-06-30: 9,479,000

FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNXT EBITDA Yield Metrics

EBITDA YIELD

N/A

RNXT Competitors' EBITDA Yield

RNXT

RenovoRx, Inc.

Current

Market Cap

$62.62M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs RNXT

Market Cap

$62.78M

EBITDA Yield

N/A

TTM Avg

0.88%

3Y Avg

0.88%

5Y Avg

0.88%

INCR

InterCure Ltd.

vs RNXT

Market Cap

$63.02M

EBITDA Yield

N/A

TTM Avg

13.59%

3Y Avg

8.25%

5Y Avg

8.86%

PLRX

Pliant Therapeutics, Inc.

vs RNXT

Market Cap

$63.78M

EBITDA Yield

N/A

TTM Avg

8.85%

3Y Avg

8.85%

5Y Avg

8.85%

ALPS

Alps Group Inc

vs RNXT

Market Cap

$64.18M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs RNXT

Market Cap

$60.42M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs RNXT

Market Cap

$60.02M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XBIT

XBiotech Inc.

vs RNXT

Market Cap

$65.85M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CING

Cingulate Inc.

vs RNXT

Market Cap

$65.86M

EBITDA Yield

445.09%

TTM Avg

3466.62%

3Y Avg

3466.62%

5Y Avg

3466.62%

GOSS

Gossamer Bio, Inc.

vs RNXT

Market Cap

$65.87M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
RenovoRx, Inc. (RNXT)	$62.62M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$62.78M	N/A	0.88%	0.88%	0.88%
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	13.59%	8.25%	8.86%
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.78M	N/A	8.85%	8.85%	8.85%
Alps Group Inc (ALPS)vs ›	$64.18M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.42M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.02M	N/A	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.85M	N/A	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$65.86M	445.09%	3466.62%	3466.62%	3466.62%
Gossamer Bio, Inc. (GOSS)vs ›	$65.87M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

RNXT EBITDA Yield Metrics

RNXT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics